Suspects detained by police denied essential insulin, cancer and epilepsy drugs, damning report claims
Suspects detained in custody suites are even having emergency care withheld as a 'form of punishment', according to the study shared exclusively with The Independent.
The report has sparked calls for custody healthcare to be brought into the NHS, amid claims basic standards are not being met by private companies who currently provide it.
Deborah Cohen, chief executive for charity INQUEST, which represents families whose loved ones have died in custody, said the report is 'deeply concerning' and urged ministers to respond before the risks 'lead to catastrophe'.
'This is about the denial of life-protecting medication,' she said. 'There is the ever-present risk of death and harm. It shines a light on the standards of healthcare in police custody suites.
'This report lays bare many of the concerns INQUEST has had for decades around the standards of care afforded detainees in police custody. The reality of this, denying people medication, which is life protecting does hold the risk of death and serious harm.'
The news comes as the government has triggered 'Operation Safeguard', which allows the prison service to hold people overnight in police cells, due to overflowing jails.
Researchers from Newcastle University, and Northumbria and Durham Universities went through hundreds of hours of police logs and spent long periods in custody suites interviewing staff and detainees over 2022 and 2023. They found multiple examples of patients being denied prescription medication for diabetes, arthritis, cancer, epilepsy, PTSD, and even insulin.
Researchers claim there was 'scepticism and distrust of detained persons' medical histories,' from custody staff.
Gethin Rees, the study's principal author, said: 'The thing that struck me is... it's a really important part of criminal justice but it is largely ignored.
'We are talking about the most vulnerable people in our society. The way society should be measured is the way we treat our most vulnerable so it's vital we explore [this]...we found people wanted to get to prison because police custody was seen as worse than prison.'
Differing policies between healthcare providers covering custody meant a 'postcode lottery' on the healthcare provided and what medications were allowed, research showed.
In some suites, people were not allowed prescribed medication that was not in its original labelled box, while in others, staff did not allow any medication for the first six hours - in breach of current guidelines.
Mwenza Blell, one of the researchers who spent hours within custody suites, said: 'The option to trust people just does not seem to be real for health care professionals in custody.
'The scepticism partially derives from a risk-averse culture, driven by fears that detained persons are 'drug-seeking' and looking to 'top-up' for free.'
Stephanie Mulhern, who interviewed people who had experience of custody, told The Independent that one patient she met who had been denied prescription methadone had experienced such bad withdrawal symptoms that they admitted to crimes they did not commit, so they could be remanded to prison where they would be allowed their prescription again.
'People were so desperate to ease their suffering that they then ended up relapsing and scoring drugs and forced back into a cycle of committing further crime,' she added.
A core issue raised in the report was the lack of access to healthcare professionals in each police station, which impacts the ability of people to access healthcare and medication when they need it.
Custody healthcare is commissioned by police forces and is largely provided by private companies, which the report suggests leads to 'strategic' cost-cutting.
Dr Mwenza said bringing back the provision of healthcare in custody into the NHS 'would be useful', adding: 'I began to wonder how they know what standards should be.'
The Home Office was contacted for comment. A department source said the report was being reviewed with the National Police Chiefs Council to see if any issues require addressing nationally.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Guardian
26 minutes ago
- South Wales Guardian
Expectant mothers to bypass GP and go straight to midwife
Traditionally, mothers-to-be made an appointment with their family doctor to tell them the news before being booked in with their midwife. And in recent years, online self-referral has been introduced by local health bodies. But NHS leaders said that only half of expectant mothers were using these services directly, with many going 'unnecessarily' to their GP to access maternity care. Women will now be able to refer themselves to local maternity services 'at the touch of a button' via which will give them faster first appointments, NHS England said. It is hoped that the move could free up tens of thousands of appointments for overstretched GPs. Officials stressed that women can still see a GP if they would like to, adding that some with long-term health conditions will need to discuss changes to their care or treatment plans with a doctor. Just found out you're pregnant? You can now refer yourself to maternity services – no need to see your GP first. It's quick, simple, and gets your care started early. Start your pregnancy journey at UHS here: #MaternityMatters — University Hospital Southampton 💙 (@UHSFT) July 9, 2025 Health officials said that first midwife appointments are 'vital', but only 62% of these happened within the first 10 weeks of pregnancy in 2023/24. There are around 600,000 babies born each year in England and Wales. NHS England said that it is estimated that the new service could lead to 180,000 fewer calls to GPs and up to 30,000 fewer general practice appointments each year. But around a quarter of local health bodies are yet to 'connect' to the national service, it added, with pregnant women in these areas able to self-refer via local trust sites. In 2024, there were 594,677 live births in England and Wales, an increase of 3,605 (0.6%) compared with 2023 (591,072). This is the first increase since 2021, although it is smaller than the 1.8% increase from 2020 to 2021 ➡️ — Office for National Statistics (ONS) (@ONS) July 1, 2025 'It's so important that newly pregnant women get the support they need as soon as possible, so this new tool makes it easier than ever to book that all-important first maternity care appointment,' said Kate Brintworth, NHS chief midwife. 'Making this process simpler at the touch of a button is a vital step in empowering women to take control of their pregnancy journey right from the very start and improving access to timely, personalised care.' Dr Claire Fuller, NHS England's national medical director, said: 'GPs are available for any pregnant women who have concerns about their pregnancy they need to discuss, or other health conditions that need monitoring, but in many cases, GP teams don't need to be the first point of contact when someone finds out they're pregnant. 'This quick and easy tool can help ease pressure on practice teams, who won't need to make the referral themselves, and by freeing up that time there will hopefully be a benefit for other patients who are looking to make an appointment with their GP.' Health and Social Care Secretary Wes Streeting said: 'Early pregnancy should be about joy and excitement – not wrestling with NHS bureaucracy to book a midwife appointment. 'That's why we've overhauled the online referral system. No more endless phone calls or form-filling. Just a simple online service that lets you book those crucial first appointments with a few clicks.' Abbie Aplin, director of maternity improvement and partnerships at the Royal College of Midwives, said: 'Giving women more control and more agency over their care during pregnancy, labour, birth and the postnatal period can only be a good thing. 'Midwives are best placed to support women to make informed choices about their care, so the earlier the better in terms of access. 'We do have to be mindful, though, of those who don't have easy access to smartphones and technology. 'We already see significant inequalities of outcome for women living with social deprivation so the NHS needs to ensure that those gaps aren't widened yet further.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'It's vital that women are able to access the most appropriate person-centred care from the earliest stages and throughout their pregnancy. 'In most cases this will be provided by midwife teams, so this initiative, as long as it is implemented correctly, makes sense. 'It's important that women in early pregnancy still know they can come to their GP directly with any concerns about their pregnancy or health – and for women with existing health conditions, we would advise that they remain in contact with their GP as their pregnancy progresses. 'Anyone that has any issues accessing online referrals can also still be referred to appropriate maternity care through their GP practice.'
South Wales Guardian
26 minutes ago
- South Wales Guardian
‘Outdated guidance' sees thousands at risk of prostate cancer ‘overtreatment'
Overtreatment of the disease can lead to side effects such as erectile dysfunction or incontinence, according to Prostate Cancer UK. Experts suggest closely monitoring certain patients can be the 'best' option for men whose cancer is unlikely to progress, although out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a 'wild west'. There are around 55,000 new cases of prostate cancer diagnosed in the UK every year. However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm. These men benefit from being closely monitored with blood tests and scans, which is known as active surveillance. Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored. However, it has not been updated since 2021, according to Prostate Cancer UK. Freedom of information (FOI) request analysis by the charity found around one in four (24%) of hospitals rely on Nice guidance alone to implement active surveillance. It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics. The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment. It also claims the outdated guidance is hindering a screening programme for prostate cancer. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: 'To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven't caught up with the clinical evidence. 'Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England. 'Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men. 'We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough.' The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions including prostate cancer or an enlarged prostate. Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms. However, there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment. Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: 'Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime. 'But Nice's outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams. 'This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects. 'Programmes for active surveillance that are standardised and individualised to a man's risk factors have been tested and proven to work.' The UK's National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out. A Nice spokesperson said: 'We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes. 'They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current. 'We are updating our prostate cancer guideline, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating.'
Glasgow Times
32 minutes ago
- Glasgow Times
‘Outdated guidance' sees thousands at risk of prostate cancer ‘overtreatment'
Overtreatment of the disease can lead to side effects such as erectile dysfunction or incontinence, according to Prostate Cancer UK. Experts suggest closely monitoring certain patients can be the 'best' option for men whose cancer is unlikely to progress, although out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a 'wild west'. There are around 55,000 new cases of prostate cancer diagnosed in the UK every year. However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm. These men benefit from being closely monitored with blood tests and scans, which is known as active surveillance. Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored. However, it has not been updated since 2021, according to Prostate Cancer UK. Freedom of information (FOI) request analysis by the charity found around one in four (24%) of hospitals rely on Nice guidance alone to implement active surveillance. It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics. The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment. It also claims the outdated guidance is hindering a screening programme for prostate cancer. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: 'To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven't caught up with the clinical evidence. 'Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England. 'Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men. 'We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough.' The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions including prostate cancer or an enlarged prostate. Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms. However, there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment. Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: 'Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime. 'But Nice's outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams. 'This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects. 'Programmes for active surveillance that are standardised and individualised to a man's risk factors have been tested and proven to work.' The UK's National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out. A Nice spokesperson said: 'We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes. 'They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current. 'We are updating our prostate cancer guideline, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating.'
